Condition: Chronic Kidney Diseases · Heart Failure With Preserved Ejection Fraction · Kidney Diseases · Sponsor: Northwestern University
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
This description comes directly from the study's public registry record.
Rupal Mehta, MD · (312) 503-1536 · rupal.mehta@northwestern.edu
Tamara Isakova, MD · (312) 503-6921 · tamara.isakova@northwestern.edu
Always discuss trial participation with your own doctor first.
| Northwestern University | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05719714